Fierce Biotech's @GabrielleMasso9 has arrived at #ASCO22 ready to report. But first, a big decision:
FierceBiotech
29.5K posts
FierceBiotech
@FierceBiotech
The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.
- Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene therapy, data that is prompting the biotech to seek accelerated approval in AIPL1-associated severe retinal dystrophy. $MGTX
- Less than two years after breaking ground on a $1.3 billion R&D center and future U.K. headquarters in London, Merck & Co. is bailing on the project and discontinuing all research operations in Britain, citing an unwelcoming business environment. $MRK
- The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi have signed a joint pledge
- In a highly anticipated article, FDA officials Vinay Prasad and Martin Makary outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies are developed and approved.
- Amid the occasional repugnance of BioTwitter, where ugly slanging matches play out as egos battle for control, Becker was its spiritual leader, quietly and bravely battling a terminal illness and using his remaining years to bring attention to HPV cancers:
- Importantly, the vaccine kept children out of hospital whether or not they had been infected with dengue before—a distinction that tripped up the rollout of Sanofi’s Dengvaxia and resulted in a sharply limited FDA approval
- Breaking news: Johnson & Johnson is closing a massive, nearly 200,000 square-foot R&D facility in the Bay Area, less than 18 months after it opened.
- Pharmas have a record $1 trillion to deploy on new biotech innovation deals. All they need is for the Federal Reserve to lower rates, according to a new report from Ernst & Young.
- Almost all the patients with depression who received Gilgamesh Pharmaceuticals’ psychedelic drug candidate went into remission.
